CYP19A1 and breast carcinoma: Three HDACi, vorinostat, and panobinostat, have been approved by the FDA and are currently being tested in clinical trials for breast cancer patients as a single agent or in combination with other standard therapies such as chemotherapies, aromatase inhibitors (exemestane), or SERM (tamoxifen) (Munster et al., 2011).